Kuwana, Masataka <br/><br/>
Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.  [electronic resource] 

 -  Annals of the rheumatic diseases  05 2020 
 - 626-634 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/annrheumdis-2019-216274  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Comorbidity<br/>Connective Tissue Diseases--diagnosis<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Intention to Treat Analysis<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Phenylpropionates--administration & dosage<br/>Proportional Hazards Models<br/>Pulmonary Arterial Hypertension--diagnosis<br/>Pyridazines--administration & dosage<br/>Risk Assessment<br/>Scleroderma, Systemic--diagnosis<br/>Tadalafil--administration & dosage<br/>Treatment Outcome<br/>Vasodilator Agents--administration & dosage